Clinical Trials Browser

Carcinoma, Hepatocellular × Pharmaceutical Preparations × 90 days × Clear all

NCT03753659 2026-03-23

IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)

Phase 2 Completed

30 enrolled 10 charts

Gastrointestinal

Carcinoma, Hepatocellular